Table 3.
Adverse events after the booster dose.
| sIPV-2bOPV-sIPV(n = 114) |
2sIPV-bOPV-bOPV(n = 54) |
2sIPV-bOPV-sIPV(n = 58) |
3sIPV-bOPV(n = 65) |
4sIPV(n = 61) |
P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of AEFI Case | Case Reporting Rate (%) | No. of AEFI Case | Case Reporting Rate (%) | No. of AEFI Case | Case Reporting Rate (%) | No. of AEFI Case | Case Reporting Rate (%) | No. of AEFI Case | Case Reporting Rate (%) | ||
| Overall | 9 | 7.09 | 1 | 1.67 | 3 | 4.69 | 3 | 4.41 | 10 | 14.93 | 0.052 |
| Vaccine-related | 7 | 5.51 | 1 | 1.67 | 3 | 4.69 | 3 | 4.41 | 10 | 14.93 | 0.043 |
| Vaccine non-related | 2 | 1.57 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1.49 | 0.767 |
| Solicited adverse events | 6 | 4.72 | 1 | 1.67 | 0 | 0 | 1 | 1.47 | 6 | 8.96 | 0.052 |
| Vaccine-related | 4 | 3.15 | 1 | 1.67 | 0 | 0 | 1 | 1.47 | 6 | 8.96 | 0.050 |
| Vaccine non-related | 2 | 1.57 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1.49 | 0.767 |
| Non-solicited adverse events | 4 | 3.15 | 0 | 0 | 3 | 4.69 | 2 | 2.94 | 4 | 5.97 | 0.399 |
| Vaccine-related | 3 | 2.36 | 0 | 0 | 3 | 4.69 | 2 | 2.94 | 4 | 5.97 | 0.309 |
| Vaccine non-related | 1 | 0.79 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.000 |
| Adverse events of grade 3 or higher | 1 | 0.79 | 1 | 1.67 | 0 | 0 | 0 | 0 | 0 | 0 | 0.552 |
| Vaccine-related | 1 | 0.79 | 1 | 1.67 | 0 | 0 | 0 | 0 | 0 | 0 | 0.552 |
| Vaccine non-related | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
sIPV = Sabin inactivated poliovirus vaccine; bOPV = bivalent oral polio vaccine.